Next Generation News and Research

RSS

US Spine introduces Phantom Plus Interbody Fusion System

US Spine® is pleased to announce the launch of the Phantom Plus™ Interbody Fusion System. Phantom Plus provides spine surgeons with next generation instrumentation and implants that offer a compliment to US Spine’s posterior fixation systems. Features include tapered leading edges for easy insertion, a higher degree of doming to more closely match endplate anatomy, anti-migration teeth, and advanced instrumentation for multiple insertion techniques.

7 Oct 2009

CryoValve SG aortic human heart valve receives Humanitarian Use Device designation

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its CryoValve® SG aortic human heart valve.

6 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

Sigma-Aldrich to distribute ThalesNano's CatCart catalyst products globally

Sigma-Aldrich announced today that it has signed a distribution agreement with ThalesNano, the world leader in bench top flow chemistry instruments, the terms of which will see Sigma-Aldrich distribute ThalesNano's complete line of approximately 400 CatCart® catalyst products for flow chemistry solutions on a global basis.

6 Oct 2009

MEF 21 certification for D-Link Xstack DES-3200 switch series

D-Link, the end-to-end computer networking solutions provider for consumer and business, today announced that its xStack® DES-3200 Series was one of the first product lines to receive MEF 21 certification from Iometrix test laboratory, the MEF authorized certification test lab.

6 Oct 2009

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

Scientists from the Baylor College of Medicine Human Genome Sequencing Center (HGSC) are expanding their fleet of advanced genomic next-generation sequencing technology from Applied Biosystems, part of Life Technologies Corporation to accelerate their studies of the genetic underpinnings of cancer and other complex human diseases.

6 Oct 2009

BIOBASE to integrate its TRANSFAC database with CLC bio's popular workbenches

Today at the Biotechnica / Bio-IT World Europe conference in Hannover, Germany, BIOBASE and CLC bio announced a partnership to integrate BIOBASE's comprehensive TRANSFAC® database with CLC bio's popular workbenches and award-winning server solution.

6 Oct 2009

Next generation remote monitoring platform to improve healthcare access

UPMC Health Plan today announced a joint initiative with BL Healthcare to address the issues of access to quality healthcare and rising healthcare costs by using technology to provide remote care over broadband. UPMC Health Plan will leverage BL Healthcare's next generation remote monitoring platform to provide unique and innovative services to their members.

6 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

Direct Flow Medical releases clinical results of its new Percutaneous Aortic Valve System

Direct Flow Medical, Inc., www.directflowmedical.com, released its 12 month data from the initial clinical trial for a new device to treat valve disease without invasive thoracic surgery. Direct Flow Medical is a privately held, emerging medical device company developing a next-generation, catheter based, percutaneous delivered prosthetic aortic valve.

6 Oct 2009

Verenium declares public offering of common stock

Verenium Corporation, a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock, and potentially warrants, in an underwritten public offering.

6 Oct 2009

BioImagene announces launch of the Virtuoso digital pathology solution

BioImagene, the leading provider of innovative digital pathology solutions, today announced the availability of the next generation of its digital pathology solution, VirtuosoTM. A highlight in this version is the ability to share cases in real time, allowing pathologists to collaborate with each other to sign out cases. Virtuoso users can participate in peer reviews, perform second-opinions for difficult cases, and guide residents in the review of cases for education.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

Conceptus obtains Ovion intellectual property rights from American Medical Systems

Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that it has acquired Ovion intellectual property rights from American Medical Systems Holdings, Inc. for a cash purchase price of $23.6 million.

6 Oct 2009

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

The Centre for Blood Research (CBR) and the Faculty of Medicine at the University of British Columbia have announced the establishment of the CSL Behring - Canada Research Chair in Endothelial Cell Biology. Over the next five years, the CBR and CSL Behring Canada, the biopharmaceutical company co-funding the chair program, will collaborate on the research and development of new therapies for patients with bleeding and immune system disorders.

5 Oct 2009

Arrayit deploys new proteomics platform

Arrayit Corporation, a life sciences and health care technology innovator, announces that on October 1st, 2009, the company deployed its next-generation proteomics platform to customers working in the areas of proteomics and in vitro molecular diagnostics.

5 Oct 2009

Innovative health care information technology solutions to improve quality of patient care

Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), provided the integrated solution to help Methodist reduce the length of stay associated with patients and help realize gains in efficiency and revenue.

5 Oct 2009

New consumer At-Home Skin Typing and Analysis Kit unveiled

Reveal Sciences, LLC, a cosmetics and aesthetics innovation company pioneering breakthrough skin care diagnostics, has announced the launch of the new consumer At-Home Skin Typing and Analysis Kit.

5 Oct 2009

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations.

5 Oct 2009

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin’s proprietary technology.

5 Oct 2009

Next Generation News and Research

US Spine introduces Phantom Plus Interbody Fusion System

CryoValve SG aortic human heart valve receives Humanitarian Use Device designation

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Sigma-Aldrich to distribute ThalesNano's CatCart catalyst products globally

MEF 21 certification for D-Link Xstack DES-3200 switch series

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

BIOBASE to integrate its TRANSFAC database with CLC bio's popular workbenches

Next generation remote monitoring platform to improve healthcare access

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Direct Flow Medical releases clinical results of its new Percutaneous Aortic Valve System

Verenium declares public offering of common stock

BioImagene announces launch of the Virtuoso digital pathology solution

Scientists identify new interference method to target cancer cells

Conceptus obtains Ovion intellectual property rights from American Medical Systems

CSL Behring - Canada Research Chair to develop therapies for treating bleeding and immune system disorders

Arrayit deploys new proteomics platform

Innovative health care information technology solutions to improve quality of patient care

New consumer At-Home Skin Typing and Analysis Kit unveiled

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News